Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39083772.
- Also identified by DOI 10.1056/NEJMoa2312302 and PMC identifier 7616361.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
We discovered high-titer neutralizing autoantibodies against interleukin-10 in a child with infantile-onset inflammatory bowel disease (IBD), a phenocopy of inborn errors of interleukin-10 signaling. After B-cell-depletion therapy and an associated decrease in the anti-interleukin-10 titer, conventional IBD therapy could be withdrawn. A second child with neutralizing anti-interleukin-10 autoantibodies had a milder course of IBD and has been treated without B-cell depletion. We conclude that neutralizing anti-interleukin-10 autoantibodies may be a causative or modifying factor in IBD, with potential implications for therapy. (Funded by the National Institute for Health and Care Research and others.).
Medical subject headings
- Antibodies, Neutralizing
- Autoantibodies
- Inflammatory Bowel Diseases
- Interleukin-10